---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-072232"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:53:30.317839+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics enters $125M ATM offering with BofA, terminates Cowen agreement

## Summary
- Enters Sales Agreement with BofA Securities for at-the-market offering of up to $125M in common stock.
- BofA will receive up to 3.0% of gross proceeds from shares sold under the agreement.
- Prior ATM agreement with Cowen terminated on June 15, 2023; no shares were sold under that agreement.
- Company may sell shares from time to time, with no obligation to sell; can suspend or terminate at any time.

## SEC filing metadata
- accession: 0001104659-23-072232
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465923072232/0001104659-23-072232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465923072232/tm2318809d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-072232
- JSON: https://secwatch.observer/filing/0001104659-23-072232.json
- Plain text: https://secwatch.observer/filing/0001104659-23-072232.txt

## Key facts
- Material Agreements
  Edgewise Therapeutics, Inc. terminated Prior Sales Agreement with Cowen and Company, LLC valued at Terminated prior to any sales of Placement Shares (effective 2023-06-15).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC
  - Value: Terminated prior to any sales of Placement Shares
  - Effective: 2023-06-15
  source text: In connection with the Company’s entry into the Sales Agreement, on June 15, 2023, the Company delivered written notice to Cowen to terminate the Prior Sales Agreement pursuant to Section 11(b) thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000110465923072232/0001104659-23-072232-index.htm
- Material Agreements
  Edgewise Therapeutics, Inc. entered into Sales Agreement with BofA Securities, Inc. valued at up to $125,000,000 (effective 2023-06-16).
  - Action: entry
  - Agreement: atm program
  - Counterparty: BofA Securities, Inc.
  - Value: up to $125,000,000
  - Effective: 2023-06-16
  source text: On June 16, 2023, Edgewise Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with BofA Securities, Inc. (“BofA Securities”) under which the Company may offer and sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having aggregate sales proceeds of up to $125,000,000 (the “Shares”), from time to time, through an “at the market offering” program under which BofA Securities will act as sales agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000110465923072232/0001104659-23-072232-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.